Stage
No active trials
Next date
None yet
Trials
0 active
8 in total · 3 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Biologic: IL-17A inhibitor Form: Solution for injection Route of administration: Subcutaneous (SC)”In the company’s words, NCT05623345 on ClinicalTrials.gov
- Tested for
- Hidradenitis Suppurativa (2 trials), Psoriatic Arthritis (2 trials), Uveitis (2 trials), Plaque Psoriasis, Ankylosing Spondylitis
- Main trialPhase 3
- “Izokibep is a small protein molecule that acts as a selective, potent inhibitor of interleukin 17A, to which it binds with high affinity. This study investigates izokibep in participants with active Hidradenitis Suppurativa (HS), including tumor necrosis factor-alpha inhibitor (TNFi) naïve participants, and those who had an inadequate response or intolerance to TNFi, or for whom TNFi is contraindicated.”In the company’s words, NCT05905783 on ClinicalTrials.gov
- Other names
- ABY-035
Other drugs for Hidradenitis Suppurativa
- RuxolitinibIncyte · Novartis · Phase 3
- BimekizumabUCB Biopharma SRL · Phase 3
- PovorcitinibIncyte Corporation · Phase 3
- LutikizumabAbbVie · Phase 3
- RemibrutinibNovartis · Phase 3
- BFB759Bluefin Biomedicine, Inc. · Phase 2/3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Terminated | 24 Jul 2024 | Hidradenitis Suppurativa Study of Izokibep | |
| Phase 2/3Terminated | 30 Nov 2023 | Psoriatic Arthritis Study of Izokibep | |
| Phase 2Completed | 27 Mar 2019 | A Study to Evaluate ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis | |
| Phase 2Completed | 1 Oct 2021 | A Study to Investigate Efficacy, Tolerability and Safety of ABY-035 in Patients With Active Psoriatic Arthritis | |
| Phase 2Terminated | 11 Jul 2022 | ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis | |
| Phase 2Completed | 25 Aug 2022 | A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis | |
| Phase 2Completed | 2 Aug 2023 | Hidradenitis Suppurativa Phase 2b Study of Izokibep | |
| Phase 2Terminated | 7 Feb 2025 | Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026